Status:
UNKNOWN
Shortening Treatments Of Chronic Inflammatory Conditions
Lead Sponsor:
Centre Hospitalier Universitaire de Besancon
Conditions:
Psoriasis
Inflammatory Bowel Diseases
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Background Psoriasis is a common disease which is a source of major distress for patients and costs for the society. Treatments are effective but temporary and relapses occur, preferentially at sites ...
Eligibility Criteria
Inclusion
- Psoriasis under systemic treatment for more than a year and in remission for at least 12 weeks: Physician Global Assessment \[PGA\] score 0-1, Psoriasis Area and Severity Index \[PASI\] score ≤ 3 OR inflammatory Bowel Disease \[IBD\] (Crohn's disease or ulcerative colitis) under systemic treatment for more than a year and in deep remission (clinical and endoscopic = SES CD 0-2 score for Crohn's, endoscopic Mayo score) in whom a de-escalation of treatment is scheduled.
- Agrrement of treatment discontinuation between patient and clinician before inclusion in this study.
- Informed Consent Form signed
Exclusion
- Uncertain diagnosis
- Local immunomodulatory treatment for psoriasis ongoing or stopped for less than three weeks
Key Trial Info
Start Date :
April 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04848649
Start Date
April 1 2021
End Date
April 1 2024
Last Update
April 19 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.